Eric  Bjerkholt net worth and biography

Eric Bjerkholt Biography and Net Worth

Eric is CFO of Chinook Therapeutics. He most recently served as CFO of Aimmune Therapeutics, Inc. overseeing financial reporting, budgeting, internal controls, investor relations, business development, facilities and information technology, and also led the acquisition of Aimmune by Nestlé Health Science for $2.6 billion. Prior to Aimmune, Eric spent 13 years at Sunesis Pharmaceuticals, Inc., where in addition to CFO, he served in various capacities, including Executive Vice President of Corporate Development and Finance, Corporate Secretary and Chief Compliance Officer. Previously, Eric held senior executive finance roles at IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc. and Age Wave, LLC and spent seven years in healthcare investment banking at J.P. Morgan & Company, Inc. He is currently a member of the board of directors of Graybug Vision, Inc. as well as a member of the board of directors and chair of the audit committee of Cerus Corporation. Eric holds an M.B.A. from Harvard Business School and a Cand.Oecon. from University of Oslo in Norway.

What is Eric Bjerkholt's net worth?

The estimated net worth of Eric Bjerkholt is at least $565,460.00 as of March 27th, 2024. Mr. Bjerkholt owns 14,000 shares of Chinook Therapeutics stock worth more than $565,460 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Bjerkholt may own. Learn More about Eric Bjerkholt's net worth.

How old is Eric Bjerkholt?

Mr. Bjerkholt is currently 63 years old. There are 4 older executives and no younger executives at Chinook Therapeutics. Learn More on Eric Bjerkholt's age.

How do I contact Eric Bjerkholt?

The corporate mailing address for Mr. Bjerkholt and other Chinook Therapeutics executives is 740 HEINZ AVENUE, BERKELEY CA, 94710. Chinook Therapeutics can also be reached via phone at (206) 485-7241 and via email at [email protected]. Learn More on Eric Bjerkholt's contact information.

Has Eric Bjerkholt been buying or selling shares of Chinook Therapeutics?

Eric Bjerkholt has not been actively trading shares of Chinook Therapeutics within the last three months. Most recently, Eric Bjerkholt sold 857 shares of the business's stock in a transaction on Friday, February 10th. The shares were sold at an average price of $23.75, for a transaction totalling $20,353.75. Following the completion of the sale, the chief financial officer now directly owns 38,867 shares of the company's stock, valued at $923,091.25. Learn More on Eric Bjerkholt's trading history.

Who are Chinook Therapeutics' active insiders?

Chinook Therapeutics' insider roster includes Srinivas Akkaraju (Director), Eric Bjerkholt (CFO), Jerel Davis (Director), Eric Dobmeier (CEO), Tom Frohlich (COO), Alan Glicklich (Insider), and Andrew King (Insider). Learn More on Chinook Therapeutics' active insiders.

Are insiders buying or selling shares of Chinook Therapeutics?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 2,323 shares worth more than $72,498.54. The most recent insider tranaction occured on August, 1st when insider Andrew James King sold 1,168 shares worth more than $45,587.04. Insiders at Chinook Therapeutics own 16.8% of the company. Learn More about insider trades at Chinook Therapeutics.

Information on this page was last updated on 8/1/2023.

Eric Bjerkholt Insider Trading History at Chinook Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/10/2023Sell857$23.75$20,353.7538,867View SEC Filing Icon  
1/31/2023Sell2,891$24.68$71,349.8837,289View SEC Filing Icon  
12/1/2022Sell5,770$22.29$128,613.3032,847View SEC Filing Icon  
2/11/2022Sell895$12.74$11,402.30View SEC Filing Icon  
See Full Table

Eric Bjerkholt Buying and Selling Activity at Chinook Therapeutics

This chart shows Eric Bjerkholt's buying and selling at Chinook Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chinook Therapeutics Company Overview

Chinook Therapeutics logo
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.
Read More

Today's Range

Now: $40.39
Low: $40.39
High: $40.39

50 Day Range

MA: $39.86
Low: $38.66
High: $40.39

2 Week Range

Now: $40.39
Low: $18.34
High: $40.51

Volume

N/A

Average Volume

1,186,257 shs

Market Capitalization

$2.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34